Agios Pharmaceuticals

Based: Cambridge, MA
Stock symbol: AGIO
Range: $14 to $16
IPO price: $18
Close Oct. 17: $28.40
Change: Up 58%
Raised: $122 million

The scoop: When Agios first laid out its plans for an IPO, the biotech used $86 million as its target--a common marker for S-1s. When it rolled out a few weeks later, the take was $106 million for a price well over the range. And the stock price has only headed north from there. CEO David Schenkein was part of Millennium's Velcade crew before he went on to work at Genentech. Then he rejoined some of his colleagues at Millennium who went on to set up Third Rock, which funded the company--with Arch and Flagship--and dived into cancer metabolism. A big partnership with Celgene ($CELG) which included a $130 million upfront (and popped up several times among the top 10 this year) just seemed natural. Agios scored big with investors even though the company had yet to enter into the clinic with its cancer drugs. In September investigators enrolled the first patient in a Phase I study of AG-221 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-2 mutation. Agios is a 2009 Fierce 15 company.

For more:
Special report: 2009 Fierce 15 - Agios Pharmaceuticals
Agios Pharma launches oversized $106M IPO
Agios selling $86M IPO to fund its first cancer drug trials
Celgene-backed Agios and Foundation partner in breakthrough cancer strategy
Agios compounds could be alternative treatment to chemo for leukemia, brain cancer

Agios Pharmaceuticals
Read more on

Suggested Articles

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.

Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.

The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.